|
|
| Oliveira,G.A.P.; Costa,E.S.; Freitas,M.S.; Dutra,F.F.; Maia,S.F.; Guerra,M.C.; Tabernero,M.D.; Borojevic,R.; Otazu,I.B.; Silva,J.L.. |
| Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3% of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic transplantation. We describe the positive responses of 2 children (case 1 - from a 7-year-old male since May 2005; case 2 - from a 5-year-old female since June 2006) with Philadelphia-positive chromosome CML treated with imatinib (300 mg/day, orally) for up to 28 months, as evaluated by morphological, cytogenetic, and molecular approaches. Our patients are alive, are in the chronic phase, and are in... |
| Tipo: Info:eu-repo/semantics/report |
Palavras-chave: Chronic myeloid leukemia; Imatinib mesylate; Minimal residual disease; Children. |
| Ano: 2010 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010000600009 |
| |
